 | Up a level |
Van Mieghem, Nicolas M; Unverdorben, Martin; Hengstenberg, Christian; Möllmann, Helge; Mehran, Roxana; López-Otero, Diego; Nombela-Franco, Luis; Moreno, Raul; Nordbeck, Peter; Thiele, Holger; Lang, Irene; Zamorano, José L; Shawl, Fayaz; Yamamoto, Masanori; Watanabe, Yusuke; Hayashida, Kentaro; Hambrecht, Rainer; Meincke, Felix; Vranckx, Pascal; Jin, James; ... (2021). Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. The New England journal of medicine, 385(23), pp. 2150-2160. Massachusetts Medical Society 10.1056/NEJMoa2111016
Tangelder, Marco J D; Nwachuku, Chuke E; Jaff, Michael; Baumgartner, Iris; Duggal, Anil; Adams, George; Ansel, Gary; Grosso, Michael; Mercuri, Michele; Shi, Minggao; Minar, Erich; Moll, Frans L (2015). A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention. Journal of endovascular therapy, 22(2), pp. 261-268. International Society of Endovascular Specialists 10.1177/1526602815574687
